This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Bullous Diseases  • Nail Diseases  • Dermatologic Disorders, Other  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic

Pitiporn Suwattee, MD, FRCPC; Steven Chow, MD, MS; Brian C. Berg, MD; Erin M. Warshaw, MD, MS

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Sunitinib (SU011248) (Sutent; Pfizer Inc, New York, New York) is an oral multikinase phosphorylation inhibitor of receptor tyrosine kinases (RTKs), which are implicated in tumor growth, angiogenesis, and metastasis of cancer. Although it is approved for use in the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma, sunitinib has also been shown to be efficacious in treating neuroendocrine, colon, and breast cancers.¹ Dermatologic adverse effects include rash, skin discoloration, hair color changes, xerosis, alopecia, and seborrheic dermatitis–like reactions.² Palmoplantar erythrodysesthesia (PPE) was reported in 12% to 14% of patients in large phase 2 and 3 studies.³ To our knowledge, we describe herein the first case of sunitinib-related intense periungual erythema and severe mucositis in addition to bullous PPE.

Report of a Case

A 59-year-old man was seen for tender erythema and swelling of the . . . [Full Text of this Article]

Comment

AUTHOR INFORMATION